Development of Blood–Brain Barrier Permeable Nitrocatechol-Based Catechol<i>O</i>-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity
Tiago Silva(Universidade do Porto), Fernanda Borges(Universidade do Porto), Loreto Martínez‐González(Consejo Superior de Investigaciones Científicas), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Arash Shakeri(University of Waterloo), Paula Serrão(Universidade do Porto), Eugenio Uriarte(Rede de Química e Tecnologia), Fernando Remião(Universidade do Porto), Patrı́cio Soares-da-Silva(Universidade do Porto), Maria João Valente(Rede de Química e Tecnologia), Jorge Garrido(Polytechnic Institute of Porto), Daniel I. Pérez(Cedars-Sinai Medical Center), Tarek Mohamed(University of Waterloo), Praveen P. N. Rao(University of Leicester)
Cited by 40
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293